Zymeworks Appoints Dr. Paul Moore as Chief Scientific Officer
Dr. Moore will lead Zymeworks’ Early Research & Development Group responsible for advancing the Company’s next-generation of multispecific antibody programs and antibody drug... | June 27, 2022
Source: marketscreener.com